{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:13:56Z","timestamp":1788938036390,"version":"build-2803163510"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG\/2019\/004018"],"award-info":[{"award-number":["CRG\/2019\/004018"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.semcancer.2023.01.002","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T10:25:06Z","timestamp":1674037506000},"page":"38-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors"],"prefix":"10.1016","volume":"89","author":[{"given":"Anas","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summya","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis Ahmad","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah S.","family":"Alawam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ibrahim","family":"Alghonaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Shadab","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2023.01.002_bib1","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2023.01.002_bib2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2023.01.002_bib3","unstructured":"A. Batool, A. Kasi, Leptomeningeal Carcinomatosis, in: StatPearls, StatPearls Publishing, Treasure Island (FL), 2022. \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499862\/\u3009 (Accessed 11 June 2022)."},{"key":"10.1016\/j.semcancer.2023.01.002_bib4","first-page":"57","article-title":"Systemic cancer therapy: achievements and challenges that lie ahead","volume":"4","author":"Palumbo","year":"2013","journal-title":"Front. Pharmscol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for cancer therapy: current progress and challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.semcancer.2023.01.002_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2022.03.026","article-title":"Advancement of cancer immunotherapy using nanoparticles-based nanomedicine","author":"Gowd","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3390\/cells8091013","article-title":"Highlights in resistance mechanism pathways for combination therapy","volume":"8","author":"Delou","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.semcancer.2023.01.002_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00048","article-title":"Signal transducer and activator of transcription (STATs) proteins in cancer and inflammation: functions and therapeutic implication","volume":"9","author":"Loh","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib9","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.2147\/CMAR.S174476","article-title":"Abnormal microRNA expression in the course of hematological malignancies","volume":"10","author":"Szymczyk","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.semcancer.2023.01.002_bib10","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.3390\/pharmaceutics13122116","article-title":"Nanoparticle-Based RNAi therapeutics targeting cancer stem cells: update and prospective","volume":"13","author":"Tang","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.semcancer.2023.01.002_bib11","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/MD.0000000000004765","article-title":"Cancer stem cell signaling pathways","volume":"95","author":"Matsui","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.semcancer.2023.01.002_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/07357907.2020.1721523","article-title":"Ras-mediated activation of NF-\u03baB and DNA damage response in carcinogenesis","volume":"38","author":"Ahmad","year":"2020","journal-title":"Cancer Investig."},{"key":"10.1016\/j.semcancer.2023.01.002_bib13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2174\/0929867321666141106124315","article-title":"Targeting the NF\u03baB signaling pathways for breast cancer prevention and therapy","volume":"22","author":"Wang","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.semcancer.2023.01.002_bib14","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.3390\/cancers13174363","article-title":"Apoptosis deregulation and the development of cancer multi-drug resistance","volume":"13","author":"Neophytou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2023.01.002_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1201\/9780429399039-2","article-title":"Nanocarriers as an emerging platform for cancer therapy","author":"Peer","year":"2020","journal-title":"Nano-Enabled Med. Appl."},{"key":"10.1016\/j.semcancer.2023.01.002_bib16","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.17140\/TFMOJ-1-e005","article-title":"Selective targeting of cancer cells using personalized nanomedicine","volume":"1","author":"Gupta","year":"2016","journal-title":"Toxicol. Forensic Med. Open J."},{"key":"10.1016\/j.semcancer.2023.01.002_bib17","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.2174\/1568026620666200616133814","article-title":"Understanding the monoclonal antibody involvement in targeting the activation of tumor suppressor genes","volume":"20","author":"Mishra","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.semcancer.2023.01.002_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6313242","article-title":"A perspective review on the role of nanomedicine in the modulation of TNF-TNFR2 axis in breast cancer immunotherapy","volume":"2019","author":"Al-Hatamleh","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2023.01.002_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fphar.2018.00027","article-title":"Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types","volume":"9","author":"Kou","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2017.01.011","article-title":"Drug delivery research for the future: expanding the nano horizons and beyond","volume":"246","author":"Mitragotri","year":"2017","journal-title":"J. Control Release"},{"key":"10.1016\/j.semcancer.2023.01.002_bib23","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1021\/acs.bioconjchem.8b00026","article-title":"Probing cellular processes using engineered nanoparticles","volume":"29","author":"Hossen","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.semcancer.2023.01.002_bib24","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1021\/acsnano.1c11070","article-title":"Reversing the epithelial\u2013mesenchymal transition in metastatic cancer cells using CD146-targeted black phosphorus nanosheets and a mild photothermal treatment","volume":"16","author":"Liu","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.semcancer.2023.01.002_bib25","doi-asserted-by":"crossref","first-page":"12567","DOI":"10.1021\/acsnano.1c02103","article-title":"Nanotechnology for boosting cancer immunotherapy and remodeling tumor microenvironment: the horizons in cancer treatment","volume":"15","author":"Gao","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.semcancer.2023.01.002_bib26","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1021\/acsnano.2c01252","article-title":"Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with immune modulatory drugs","volume":"16","author":"Nel","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.semcancer.2023.01.002_bib27","doi-asserted-by":"crossref","first-page":"6620","DOI":"10.1021\/acsnano.8b01482","article-title":"Reversibly stabilized polycation nanoparticles for combination treatment of early-and late-stage metastatic breast cancer","volume":"12","author":"Chen","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.semcancer.2023.01.002_bib28","doi-asserted-by":"crossref","first-page":"10695","DOI":"10.1021\/acsnano.5b05974","article-title":"Trimodal therapy: combining hyperthermia with repurposed bexarotene and ultrasound for treating liver cancer","volume":"9","author":"Misra","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.semcancer.2023.01.002_bib29","doi-asserted-by":"crossref","first-page":"8959","DOI":"10.1021\/nn501589f","article-title":"NanoScript: a nanoparticle-based artificial transcription factor for effective gene regulation","volume":"8","author":"Patel","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.semcancer.2023.01.002_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.trecan.2015.07.001","article-title":"Targeting transcription factors in cancer","volume":"1","author":"Bhagwat","year":"2015","journal-title":"Trends Cancer"},{"key":"10.1016\/j.semcancer.2023.01.002_bib31","first-page":"1","article-title":"Ageing and rejuvenation of tissue stem cells and their niches","author":"Brunet","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib32","first-page":"1","article-title":"Aristolochic acid-associated cancers: a public health risk in need of global action","author":"Das","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2023.01.002_bib33","first-page":"1","article-title":"Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies","author":"Gao","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2023.01.002_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","article-title":"Targeting transcription cycles in cancer","volume":"22","author":"Vervoort","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2023.01.002_bib35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nrc906","article-title":"Transcription factors as targets for cancer therapy","volume":"2","author":"Darnell","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2023.01.002_bib36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41568-021-00367-9","article-title":"MYC protein interactors in gene transcription and cancer","volume":"21","author":"Lourenco","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2023.01.002_bib37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc3496","article-title":"Dysregulation of the basal RNA polymerase transcription apparatus in cancer","volume":"13","author":"Bywater","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2023.01.002_bib38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri2818","article-title":"NFAT, immunity and cancer: a transcription factor comes of age","volume":"10","author":"M\u00fcller","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semcancer.2016.03.005","article-title":"Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds","volume":"40\u201341","author":"Shanmugam","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.semcancer.2013.05.008","article-title":"Regulation of autophagy by stress-responsive transcription factors","volume":"23","author":"Pietrocola","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semcancer.2019.06.016","article-title":"Transcription factors in SOX family: Potent regulators for cancer initiation and development in the human body","volume":"67","author":"Kumar","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib42","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41467-022-28341-5","article-title":"Human transcription factor protein interaction networks","volume":"13","author":"G\u00f6\u00f6s","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2023.01.002_bib43","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/1471-2407-14-708","article-title":"Large differences in global transcriptional regulatory programs of normal and tumor colon cells","volume":"14","author":"Cordero","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2023.01.002_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.681377","article-title":"Transcription factors: the fulcrum between cell development and carcinogenesis","volume":"11","author":"Islam","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.920492","article-title":"DNA- and RNA-binding proteins linked transcriptional control and alternative splicing together in a two-layer regulatory network system of chronic myeloid leukemia","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.semcancer.2023.01.002_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13048-021-00938-2","article-title":"Construction and validation of a transcription factors-based prognostic signature for ovarian cancer","volume":"15","author":"Cheng","year":"2022","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.semcancer.2023.01.002_bib47","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/cells9030760","article-title":"Transcription factors in cancer: when alternative splicing determines opposite cell fates","volume":"9","author":"Belluti","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.semcancer.2023.01.002_bib48","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.biocel.2012.08.022","article-title":"Cancer stem cells","volume":"44","author":"Yu","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib49","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5416923","article-title":"Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.semcancer.2023.01.002_bib50","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1021\/acs.jmedchem.2c00024","article-title":"The progress and promise of RNA medicine\u2500an arsenal of targeted treatments","volume":"65","author":"Sasso","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.semcancer.2023.01.002_bib51","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1073\/pnas.1102454108","article-title":"Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state","volume":"108","author":"Chaffer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.semcancer.2023.01.002_bib52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.stem.2015.08.014","article-title":"Therapeutic implications of cellular heterogeneity and plasticity in breast cancer","volume":"17","author":"Brooks","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.semcancer.2023.01.002_bib53","first-page":"251","article-title":"Targeting cancer stem cells by using the nanoparticles","volume":"10","author":"Hong","year":"2015","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.semcancer.2023.01.002_bib54","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1080\/21645515.2017.1327107","article-title":"Transforming growth factor-\u03b2: a therapeutic target for cancer","volume":"13","author":"Haque","year":"2017","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.semcancer.2023.01.002_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.biomaterials.2015.12.014","article-title":"Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-\u03b2 signaling pathway inhibition","volume":"82","author":"Zuo","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.semcancer.2023.01.002_bib56","doi-asserted-by":"crossref","first-page":"10048","DOI":"10.1021\/nn404083m","article-title":"Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice","volume":"7","author":"Meng","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.semcancer.2023.01.002_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002508","article-title":"Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NF\u03baB axis","volume":"9","author":"Sun","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2023.01.002_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120946","article-title":"Urinary exosomes-based engineered nanovectors for homologously targeted chemo-chemodynamic prostate cancer therapy via abrogating EGFR\/AKT\/NF-kB\/IkB signaling","volume":"275","author":"Pan","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.semcancer.2023.01.002_bib59","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.2147\/IJN.S243657","article-title":"Enhanced chemotherapeutic efficacy of PLGA-encapsulated epigallocatechin gallate (EGCG) against human lung cancer","volume":"15","author":"Zhang","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.semcancer.2023.01.002_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119997","article-title":"Catcher in the rel: Nanoparticles-antibody conjugate as NF-\u03baB nuclear translocation blocker","volume":"246","author":"Chen","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.semcancer.2023.01.002_bib61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.semcancer.2022.09.003","article-title":"Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy","volume":"86","author":"Kumar","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.nano.2017.11.015","article-title":"Delivery of NF-\u03baB shRNA using carbamate-mannose modified PEI for eliminating cancer stem cells","volume":"14","author":"Ke","year":"2018","journal-title":"Nanomed.: Nanotechnol. Biol. Med."},{"key":"10.1016\/j.semcancer.2023.01.002_bib63","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.3390\/ijms22115760","article-title":"Curcumin-loaded nanoparticles impair the pro-tumor activity of acid-stressed MSC in an in vitro model of osteosarcoma","volume":"22","author":"Di Pompo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2023.01.002_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111422","article-title":"Lactoferrin-dual drug nanoconjugate: Synergistic anti-tumor efficacy of docetaxel and the NF-\u03baB inhibitor celastrol","volume":"118","author":"Abdelmoneem","year":"2021","journal-title":"Mater. Sci. Eng.: C"},{"key":"10.1016\/j.semcancer.2023.01.002_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120290","article-title":"Fibrinolytic tissue plasminogen activator installed redox-active nanoparticles (t-PA@ iRNP) for cancer therapy","volume":"259","author":"Mei","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.semcancer.2023.01.002_bib66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijbiomac.2019.12.266","article-title":"Alginate based tamoxifen\/metal dual core-folate decorated shell: nanocomposite targeted therapy for breast cancer via ROS-driven NF-\u03baB pathway modulation","volume":"146","author":"Ibrahim","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib67","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/bph.15373","article-title":"STAT3\/NF-\u03baB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers\/PD-L1 antibody immunomodulatory therapy in breast cancer","volume":"178","author":"Cavalcante","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib68","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3390\/molecules24112103","article-title":"Novel targeted nano-parthenolide molecule against NF-kB in acute myeloid leukemia","volume":"24","author":"Darwish","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.semcancer.2023.01.002_bib69","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.apsb.2018.12.009","article-title":"Neutrophil-mimicking therapeutic nanoparticles for targeted chemotherapy of pancreatic carcinoma","volume":"9","author":"Cao","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.semcancer.2023.01.002_bib70","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/10717544.2019.1667454","article-title":"Fabrication and characterization of solid lipid nano-formulation of astraxanthin against DMBA-induced breast cancer via Nrf-2-Keap1 and NF-kB and mTOR\/Maf-1\/PTEN pathway","volume":"26","author":"Sun","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.semcancer.2023.01.002_bib71","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1166\/jbn.2022.3266","article-title":"Gold-nanoparticle-conjugated citrate inhibits tumor necrosis factor-\u03b1 expression via suppression of nuclear factor kappa B (NF-\u03baB) activation in breast cancer cells","volume":"18","author":"Aljohani","year":"2022","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111109","article-title":"Nanoparticle mediated codelivery of nifuratel and doxorubicin for synergistic anticancer therapy through STAT3 inhibition","volume":"193","author":"Zheng","year":"2020","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.semcancer.2023.01.002_bib73","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.7150\/thno.32462","article-title":"ZnAs@ SiO2 nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1\/JAK2\/STAT3 signaling","volume":"9","author":"Huang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.semcancer.2023.01.002_bib74","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00262-019-02301-3","article-title":"STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes","volume":"68","author":"Andersen","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.semcancer.2023.01.002_bib75","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/cancers11020248","article-title":"Decoration of anti-CD38 on nanoparticles carrying a STAT3 inhibitor can improve the therapeutic efficacy against myeloma","volume":"11","author":"Huang","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2023.01.002_bib76","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3892\/mmr.2017.6583","article-title":"Inhibition of prostate cancer RM1 cell growth in vitro by hydroxyapatite nanoparticle-delivered short hairpin RNAs against Stat3","volume":"16","author":"Liang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.semcancer.2023.01.002_bib77","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3389\/fphar.2018.01214","article-title":"Biodegradable nanoparticles mediated co-delivery of erlotinib (ELTN) and fedratinib (FDTN) toward the treatment of eltn-resistant non-small cell lung cancer (NSCLC) via suppression of the JAK2\/STAT3 signaling pathway","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2018.04.023","article-title":"Inorganic kernel-Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R","volume":"279","author":"Shi","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.semcancer.2023.01.002_bib79","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1021\/acs.molpharmaceut.6b01119","article-title":"Self-Associating Poly (ethylene oxide)-block-poly (\u03b1-carboxyl-\u03b5-caprolactone) drug conjugates for the delivery of STAT3 Inhibitor JSI-124: potential application in cancer immunotherapy","volume":"14","author":"Garg","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.semcancer.2023.01.002_bib80","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/1061186X.2016.1258567","article-title":"Co-delivery of curcumin and STAT3 siRNA using deformable cationic liposomes to treat skin cancer","volume":"25","author":"Jose","year":"2017","journal-title":"J. Drug Target."},{"key":"10.1016\/j.semcancer.2023.01.002_bib81","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijpharm.2017.03.087","article-title":"Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles","volume":"525","author":"Labala","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.semcancer.2023.01.002_bib82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2017.04.034","article-title":"Preparation and characterization of lipid nanoparticle\/pDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells","volume":"525","author":"Kotmak\u00e7\u0131","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.semcancer.2023.01.002_bib83","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.colsurfb.2016.05.076","article-title":"Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma","volume":"146","author":"Labala","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.semcancer.2023.01.002_bib84","article-title":"STAT3 decoy oligodeoxynucleotides-loaded solid lipid nanoparticles induce cell death and inhibit invasion in ovarian cancer cells","volume":"10","author":"Ma","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2023.01.002_bib85","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3390\/molecules21111507","article-title":"TTF1, in the form of nanoparticles, inhibits angiogenesis, cell migration and cell invasion in vitro and in vivo in human hepatoma through STAT3 regulation","volume":"21","author":"Xiao","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.semcancer.2023.01.002_bib86","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.7150\/thno.12822","article-title":"Ultrasound targeted microbubble destruction-mediated delivery of a transcription factor decoy inhibits STAT3 signaling and tumor growth","volume":"5","author":"Kopechek","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.semcancer.2023.01.002_bib87","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.biomaterials.2014.10.050","article-title":"Nanovaccine loaded with poly I: C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo","volume":"38","author":"Luo","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.semcancer.2023.01.002_bib88","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.toxlet.2014.01.009","article-title":"Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo","volume":"225","author":"Das","year":"2014","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.semcancer.2023.01.002_bib89","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.2147\/IJN.S33666","article-title":"PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells","volume":"7","author":"Su","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.semcancer.2023.01.002_bib90","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/aja.2010.167","article-title":"Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo","volume":"13","author":"Liang","year":"2011","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.semcancer.2023.01.002_bib91","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1021\/mp900145g","article-title":"Development of a Poly (D, L-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy","volume":"7","author":"Molavi","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.semcancer.2023.01.002_bib92","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.biomaterials.2009.11.003","article-title":"The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine","volume":"31","author":"Alshamsan","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.semcancer.2023.01.002_bib93","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijpharm.2007.06.032","article-title":"Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors","volume":"347","author":"Molavi","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.semcancer.2023.01.002_bib94","doi-asserted-by":"crossref","first-page":"46626","DOI":"10.1021\/acsami.9b18730","article-title":"JQ1-loaded polydopamine nanoplatform inhibits c-MYC\/programmed cell death ligand 1 to enhance photothermal therapy for triple-negative breast cancer","volume":"11","author":"Tian","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.semcancer.2023.01.002_bib95","doi-asserted-by":"crossref","first-page":"8459","DOI":"10.1016\/j.biomaterials.2013.07.050","article-title":"Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.semcancer.2023.01.002_bib96","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1158\/1535-7163.MCT-14-0970","article-title":"RNA interference using c-Myc\u2013conjugated nanoparticles suppresses breast and colorectal cancer models","volume":"14","author":"Tangudu","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.semcancer.2023.01.002_bib97","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.7150\/thno.44523","article-title":"Nanotherapy delivery of c-myc inhibitor targets protumor macrophages and preserves antitumor macrophages in breast cancer","volume":"10","author":"Esser","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.semcancer.2023.01.002_bib98","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.18632\/oncotarget.22342","article-title":"Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)","volume":"9","author":"Dhanasekaran","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2023.01.002_bib99","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2217\/nnm-2020-0156","article-title":"Nanoformulation of PROteolysis TArgeting Chimera targeting \u2018undruggable\u2019 c-Myc for the treatment of pancreatic cancer","volume":"15","author":"Saraswat","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.semcancer.2023.01.002_bib100","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1166\/jbn.2020.2960","article-title":"Enhanced suppression of disulfide cross-linking micelles nanocarriers loaded miR-145 delivering system via down-regulation of MYC and FSCN1 in colon cancer cells","volume":"16","author":"Zhai","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121607","article-title":"Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC\/BCL6-positive double-hit diffuse large B-cell lymphoma","volume":"287","author":"Yang","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.semcancer.2023.01.002_bib102","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jconrel.2020.04.053","article-title":"ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice","volume":"323","author":"Wang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.semcancer.2023.01.002_bib103","doi-asserted-by":"crossref","DOI":"10.1088\/1748-605X\/abcae2","article-title":"Application of ZnO\/CNT@Fe3O4nanocomposite in amplifying the anti-leukemic effects of Imatinib: a novel strategy to adjuvant therapy in chronic myeloid leukemia","volume":"16","author":"Yousefi","year":"2021","journal-title":"Biomed. Mater."},{"key":"10.1016\/j.semcancer.2023.01.002_bib104","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/20\/12\/125101","article-title":"Synthesis and characterization of polyamidoamine dendrimer-coated multi-walled carbon nanotubes and their application in gene delivery systems","volume":"20","author":"Pan","year":"2009","journal-title":"Nanotechnology"},{"key":"10.1016\/j.semcancer.2023.01.002_bib105","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3109\/13880209.2014.880489","article-title":"Preparation and evaluation of nanoparticles loading plasmid DNAs inserted with siRNA fragments targeting c-Myc gene","volume":"52","author":"Ma","year":"2014","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib106","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1080\/21691401.2018.1489266","article-title":"Gold nano-particles (AuNPs) carrying miR-326 targets PDK1\/AKT\/c-myc axis in hepatocellular carcinoma","volume":"47","author":"Mo","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.semcancer.2023.01.002_bib107","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1158\/1535-7163.MCT-14-0774-T","article-title":"Small molecule MYC inhibitor conjugated to integrin-targeted nanoparticles extends survival in a mouse model of disseminated multiple myeloma","volume":"14","author":"Soodgupta","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.semcancer.2023.01.002_bib108","doi-asserted-by":"crossref","first-page":"22639","DOI":"10.1074\/jbc.M110.125906","article-title":"Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer*","volume":"285","author":"Chen","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2023.01.002_bib109","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/1535-7163.MCT-14-0556","article-title":"Multifunctional polymeric micelles Co-loaded with anti\u2013survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer","volume":"14","author":"Salzano","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.semcancer.2023.01.002_bib110","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.nano.2016.11.010","article-title":"Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models","volume":"13","author":"Roberts","year":"2017","journal-title":"Nanomed.: Nanotechnol., Biol. Med."},{"key":"10.1016\/j.semcancer.2023.01.002_bib111","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.biomaterials.2012.10.057","article-title":"Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI\/TPGS complex nanoparticles","volume":"34","author":"Shen","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.semcancer.2023.01.002_bib112","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/382745","article-title":"RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis","volume":"2015","author":"Finlay","year":"2015","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.semcancer.2023.01.002_bib113","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.nano.2018.04.008","article-title":"Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer","volume":"14","author":"Shahin","year":"2018","journal-title":"Nanomed.: Nanotechnol. Biol. Med."},{"key":"10.1016\/j.semcancer.2023.01.002_bib114","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/0008-5472.CAN-15-2951","article-title":"CRLX101, a nanoparticle\u2013drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF1\u03b1","volume":"77","author":"Tian","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2023.01.002_bib115","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/1535-7163.MCT-20-0228","article-title":"Antitumor activity of NLG207 (formerly CRLX101) in combination with enzalutamide in preclinical prostate cancer models","volume":"20","author":"Schmidt","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.semcancer.2023.01.002_bib116","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1073\/pnas.1603018113","article-title":"CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing","volume":"113","author":"Clark","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.semcancer.2023.01.002_bib117","doi-asserted-by":"crossref","first-page":"42408","DOI":"10.18632\/oncotarget.9878","article-title":"Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis","volume":"7","author":"Lin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2023.01.002_bib118","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-015-3349-8","article-title":"CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer","volume":"150","author":"Conley","year":"2015","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.semcancer.2023.01.002_bib119","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1158\/1078-0432.CCR-14-2810","article-title":"Translational impact of nanoparticle\u2013drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer","volume":"21","author":"Pham","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2023.01.002_bib120","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/0008-5472.CAN-15-3435","article-title":"Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle\u2013drug conjugate, in treatment of metastatic triple-negative breast cancer","volume":"76","author":"Pham","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2023.01.002_bib121","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.2147\/IJN.S109695","article-title":"Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis","volume":"11","author":"Yang","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.semcancer.2023.01.002_bib122","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.7150\/thno.41077","article-title":"One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X23000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X23000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:04:36Z","timestamp":1760918676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X23000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":122,"alternative-id":["S1044579X23000020"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2023.01.002","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2023.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}